Downloads: 1
| # | Blank 1 | Frequency | Blank 2 | Frequency | Blank 3 | Frequency | |
|---|---|---|---|---|---|---|---|
| 1 | 1 | 2 | 2 | 2 | |||
| 2 | 2 | patients who have not completed all standard of care treatments including surgical procedure and radiation therapy at least 59 gy r n if the | 1 | promoter in their tumor is known to be unmethylated patients are not mandated to have received chemotherapy prior to participating in this trial r n if the mgmt promoter in their tumor is known to be methylated or the mgmt promoter methylation | 1 | known | 1 |
| 3 | 3 | patients must have confirmed gbm | 1 | promoter unmethylated | 1 | is unknown at time of screening patients must have received at least one chemotherapy regimen prior to participating in this trial | 1 |
| 4 | 4 | confirmed | 1 | gene and tumor idh1 gene mutation | 1 | tumor must be mgmt promoter unmethylated by central laboratory clinical laboratory improvement amendments clia certified testing at md anderson prior to registration . if initial mgmt testing obtained at an outside institution mgmt status must be centrally retested at md anderson . | 1 |
| 5 | 5 | patient must agree to testing of gbm tumor promoter methylation status of the | 1 | promoter in their tumor is known to be methylated or the mgmt promoter | 1 | . tissue may be tested at study entry if not done previously or data may be obtained from last known test resmcLt for mgmt and idh1 . idh1 status may be assessed at study entry but mgmt status is required prior to randomization . | 1 |
| 6 | 6 | patients are not mandated to have received chemotherapy prior to participating in this trial r n if the | 1 | promoter methylation analysis of surgically resected tumor or tumor biopsy must demonstrate an unmethylated or hypomethylated mgmt promoter | 1 | is unknown at the time of screening patients must have received at least one chemotherapy regimen prior to participating in this trial | 1 |
| 7 | 8 | methylated or hypermethylated | 1 | promoter | 1 | within tumor tissue | 1 |